Scienture, LLC Secures New Patent for Innovative SCN-102
COMMACK, NY and TAMPA, FL – SCIENTURE, LLC (“the Company”), a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), is excited to announce significant progress in its intellectual property strategy. Recently, the U.S. Patent and Trademark Office (USPTO) granted a new patent titled No. 12,156,869 (the ‘869 patent) for SCN-102. This innovative product is an oral suspension formulation of Losartan Potassium designed for therapeutic use, further solidifying the Company's market position.
Understanding the New Patent Issuance
The ‘869 patent complements the existing patent No. 11,890,273 (the ‘273 patent), both of which focus on “LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE.” The patents are set to protect the stable liquid formulations of Losartan, which could transform patient treatment paradigms, especially for those requiring liquid medications.
The Vision Behind SCN-102
According to Shankar Hariharan, Ph.D., CEO of Scienture, LLC, these two patents highlight the Company’s commitment to innovation and the development of high-impact pharmaceutical products. The submission of a New Drug Application (NDA) for SCN-102 is currently under FDA review, aligning with the Company’s strategic focus on specialized needs in the pharmaceutical market.
SCN-102: A Game Changer for Patients
Narasimhan Mani, Ph.D., MBA, President of Scienture, LLC, expressed that SCN-102 has transformative potential due to its streamlined use of Losartan, a core medication for high blood pressure management. With its finalized NDA, SCN-102 aims to cater to patients needing a reliable and ready-to-use oral liquid formulation of this well-acknowledged medication.
The Impact of Merger with Scienture Holdings
This patent announcement is a powerful affirmation of the Company’s potential, particularly in light of its recent merger with Scienture Holdings, Inc. Suren Ajjarapu, Chairman of the Board, emphasized the value this merger brings to stakeholders and its beneficial implications for future projects.
Exploring SCN-102's Key Features
Scienture LLC has developed SCN-102 to optimize patient experience, featuring a user-friendly oral suspension of Losartan at a concentration of 10mg/mL. With an intention to simplify dosing regimens and enhance compliance, this product, if approved, will be the first liquid formulation available that does not necessitate compounding. Its storage advantage contributes to long shelf life at room temperature, making it both effective and accessible for diverse patients.
About Losartan
Losartan, an Angiotensin II Receptor Blocker (ARB), plays a critical role in hypertension management – it is one of the most commonly prescribed medications for high blood pressure. Industry reports indicate robust annual sales, reflecting high prescription volumes, thus confirming its integral role in public health.
Understanding Hypertension
Hypertension, defined by consistently high blood pressure readings, poses significant health risk as it can lead to serious conditions such as heart disease and stroke. Factors influencing hypertension include age, genetics, weight, diet, and lifestyle, making it a pervasive public health challenge, with millions affected nationwide.
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as a comprehensive pharmaceutical company through its subsidiaries. The mission focuses on delivering superior value to patients and healthcare providers by developing specialty products that address unmet clinical needs. With a portfolio spanning various therapeutic areas, the Company is dedicated to advancing healthcare solutions.
Frequently Asked Questions
What is SCN-102?
SCN-102 is an oral suspension formulation of Losartan Potassium aimed at improving patient convenience and adherence to hypertension treatments.
What does the new patent for SCN-102 entail?
The new patent protects the liquid formulation and methods of use for Losartan, enhancing the intellectual property framework surrounding SCN-102.
How does SCN-102 differ from traditional Losartan products?
SCN-102 is designed as a ready-to-use liquid, eliminating the need for compounding, and aims to provide a more manageable dosing experience.
What are the main implications of the recently announced merger?
The merger is expected to enhance the development capabilities and market reach of Scienture Holdings, positioning the combined entity for greater success in specialty pharma.
Who can benefit from SCN-102?
Patients who require Losartan in liquid form, particularly those who may struggle with traditional tablet dosages, stand to benefit significantly from SCN-102.
